Skip to main content
Fig. 4 | Cancer & Metabolism

Fig. 4

From: Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study

Fig. 4

Changes in body composition following dapagliflozin treatment. A Body weight significantly decreases during treatment. B Automated segmentation of CT datasets from study patients was performed to quantify the total abdominal fat and muscle. C, D Total abdominal fat and muscle volume decrease during treatment. E However, the muscle-to-fat ratio increased robustly in the extreme responder in the trial. F There is a significant positive correlation in the % change in the muscle-to-fat ratio versus % change in RECIST tumor target measurement, suggesting that maintaining muscle mass while losing fat is important for robust therapeutic response

Back to article page